| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/28/2005 | US20050089608 Exposing blood to hydrolase forming hydrolysate, enriching cmplexes by ultrafiltration in order to remove uncomplexed peptides; centrifuging second hydrolysate, mixing with soda, |
| 04/28/2005 | US20050089577 In which medicine can be easily solubilized, dispersed or suspended and which can be easily swallowed because of being liquid, has favorable working properties in sterilization and so on and a high stability, also exhibits an effect of masking bitterness |
| 04/28/2005 | US20050089575 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof |
| 04/28/2005 | US20050089574 Overcoating drug; sustained release; cardiovascular disorders; mixture of acrylic polymer and vinyl acetate polymer |
| 04/28/2005 | US20050089573 Oral pharmaceutical formulation containing ibandronate |
| 04/28/2005 | US20050089572 For oral administration in humans, stability in the acidic environment of the stomach |
| 04/28/2005 | US20050089571 Pharmaceutical formulation for the active ingredient budesonide |
| 04/28/2005 | US20050089570 Sustained release dosage form of a sustained release component and an immediate release component which is not an immediate release drug coating; burst release; able to deliver high doses of poorly soluble drugs (e.g. ibuprofen) at a controlled rate |
| 04/28/2005 | US20050089569 erodible matrix comprising drugs, coatings comprising cellulose derivatives which is insoluble in aqueous medium and a second cellulose derivative which is water soluble, plasticizers and fillers, for drug delivery into an aqueous medium by erosion at controlled rates; time-release agents |
| 04/28/2005 | US20050089568 Melt-extruded orally administrable opioid formulations |
| 04/28/2005 | US20050089567 Popping oral pharmaceutical compositions |
| 04/28/2005 | US20050089566 Heating the viscous component to a temperature of at least 45 degrees C., heating the effervescent component and then combining the two; can be tableted in an automated process and form a tablet that exhibits good structural integrity |
| 04/28/2005 | US20050089565 Methylcellulose and, as separate ingredients, a disintegrating agent, a binder, and a diluent; laxative for treating constipation |
| 04/28/2005 | US20050089564 Rapidly disintegrating methylcellulose tablets |
| 04/28/2005 | US20050089563 Rapidly disintegrating methylcellulose tablets |
| 04/28/2005 | US20050089562 First phase of a compacted mixture of methylcellulose with a viscosity greater than 1000 centipoise and an edible calcium salt, blended with a second phase that may contain a disintegrating agent, a wetting agent, a lubricant and/or a second diluent |
| 04/28/2005 | US20050089561 Blending granulated methylcellulose and granulated diluent to form an intragranulated tablet; use treating constipation |
| 04/28/2005 | US20050089560 With a diluent and a crosprovidone; treating constipation |
| 04/28/2005 | US20050089559 Flupirtine in combination with tolperisone or its analogs, such as eperisone or silperisone; pains which are accompanied by an increase in muscle tone such as neuralgia |
| 04/28/2005 | US20050089558 Treating pain; synergistic |
| 04/28/2005 | US20050089557 Tablets having improved tabletting characteristics and process for producing the same |
| 04/28/2005 | US20050089556 Composition for treating hemorrhoids |
| 04/28/2005 | US20050089555 Administering phospholipid, bile acid and water; treating adipose tissue disorders such as cellulite, tumors e.g. lipomas |
| 04/28/2005 | US20050089554 Apparatus and method for enhancing transdermal drug delivery |
| 04/28/2005 | US20050089548 Hydrocolloid film-forming material and microparticles containing active agent that rapidly disintegrates in the mouth to release the active agent such as flavorants, drugs, nutraceuticals, fragrances, food acids |
| 04/28/2005 | US20050089545 Drug delivery system for the subconjunctival administration of fine grains |
| 04/28/2005 | US20050089539 Antimicrobial compositions and methods |
| 04/28/2005 | US20050089537 Suitable for direct application to the tissues of a user in the absence of application of cosmetic substances for direct dermal and transdermal functionality containing by weight 2 to 10 % of a cross-linked silicone rubber and 90 to 98 % of cyclopentasiloxane; for lubrication of vaginal dryness |
| 04/28/2005 | US20050089535 Delivery of biologically active agents |
| 04/28/2005 | US20050089526 Monomeric unit of the complex containin HIV-1 gp120 and HIV-1 gp41, (ii) the gp4l has one or more mutations in its N-terminal helix, and (iii) the gp120 and gp41 are bound to each other by a disulfide bond between a cysteine residue introduced into the gp120 and a cysteine residue introduced into gp41 |
| 04/28/2005 | US20050089511 Methods and compositions comprising DNA damaging agents and p53 |
| 04/28/2005 | US20050089506 Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
| 04/28/2005 | US20050089504 Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules |
| 04/28/2005 | US20050089499 Forming a fermentation broth from plants inoculation with microorganisms and fermenttion to produce active component for use on skin and hair |
| 04/28/2005 | US20050089497 Mixture of 2-methylpropanediol/1,3/ monoester, surfactant, oil and water |
| 04/28/2005 | US20050089495 Transdermal transport of compounds |
| 04/28/2005 | US20050089480 Active polypeptides for nasal sprays with polysaccharides like dextran |
| 04/28/2005 | US20050089479 Delivery of sedative-hypnotics through an inhalation route |
| 04/28/2005 | US20050089478 Formeratol and budesonide for treatment of respiratory system disorders such as chronc obstructive pulmonary disease |
| 04/28/2005 | US20050089477 Medicaments |
| 04/28/2005 | US20050089476 Dissolving the active ingredient in a minimal quantity of an alcoholic solvent, sterilizing filtration, sonication |
| 04/28/2005 | US20050089475 Oral dosage form of an opioid analgesic; an aversive dye interdispersed with the opioid; the oral dosage form releases the dye upon tampering of the dosage form |
| 04/28/2005 | US20050087719 Magnetic nanodispersion with cyclodextrines and method for the production thereof |
| 04/28/2005 | US20050087198 Method for systemic drug delivery through the nail |
| 04/28/2005 | CA2576040A1 Hydrogel-containing medical articles and methods of using and making the same |
| 04/28/2005 | CA2543148A1 Mucous membrane bulging humor composition comprising chitosan derivative containing saccharide chain for use in condoscopic surgery |
| 04/28/2005 | CA2542755A1 Biguanide drug-containing jelly preparation |
| 04/28/2005 | CA2542753A1 Enhancing transdermal administration of hydrophilic drugs |
| 04/28/2005 | CA2542666A1 Aqueous aerosol preparation |
| 04/28/2005 | CA2542659A1 Chewing gum for the remineralisation of tooth enamel |
| 04/28/2005 | CA2542506A1 Pectin films prepared from gamma irradiated pectin |
| 04/28/2005 | CA2542427A1 Viral fibers |
| 04/28/2005 | CA2542074A1 Methods and reagents for the treatment of immunoinflammatory disorders |
| 04/28/2005 | CA2541265A1 Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid |
| 04/27/2005 | EP1526101A1 Method for inserting a plurality of individual sheetlike dosage forms in a dispenser by forming a multilayer pile |
| 04/27/2005 | EP1525889A1 Liquid pharmaceutical composition containing an erythropoietin derivative |
| 04/27/2005 | EP1525884A1 Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
| 04/27/2005 | EP1525883A1 Ciclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 04/27/2005 | EP1525882A1 Administration form comprising an acid-labile active compound |
| 04/27/2005 | EP1525881A2 Integrative protein-DNA cochleate fomulations and methods for transforming cells |
| 04/27/2005 | EP1525858A1 High viscosity liquid controlled delivery system |
| 04/27/2005 | EP1525549A2 Method for bioequivalence determination using expression profiling |
| 04/27/2005 | EP1525209A2 1'-, 2'- and 3' -modified nucleoside derivatives for treating flaviviridae infections |
| 04/27/2005 | EP1525200A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 04/27/2005 | EP1525000A2 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 04/27/2005 | EP1524998A1 Stable pharmaceutical composition comprising erythropoietin |
| 04/27/2005 | EP1524997A1 Stable liquid parenteral parecoxib formulation |
| 04/27/2005 | EP1524987A1 Nasal peptide pharmaceutical formulation |
| 04/27/2005 | EP1524981A1 Sustained release formulations comprising lamotrigine |
| 04/27/2005 | EP1524978A2 Taste masked sumatriptan tablets and processes for their preparation |
| 04/27/2005 | EP1524975A1 Improved transdermal delivery system for the administration of rotigotine |
| 04/27/2005 | EP1524971A1 Improved transdermal delivery system |
| 04/27/2005 | EP1524970A1 Particles which are surface coated with hyaluronan or one of the derivatives thereof and the use of same as biological vectors for active substances |
| 04/27/2005 | EP1524969A2 Microcapsules with modified release of active principles with low solubility for oral delivery |
| 04/27/2005 | EP1524968A2 Oral pharmaceutical formulation in the form of a plurality of microcapsules for prolonged release of active principle(s) with low solubility |
| 04/27/2005 | EP1524967A1 Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation |
| 04/27/2005 | EP1524966A1 Taste masked oral composition of telithromycin |
| 04/27/2005 | EP1524965A2 Stabilization of the profile of release of active substances from a formulation |
| 04/27/2005 | EP1524964A1 Process for the preparation of crystalline nano-particle dispersions |
| 04/27/2005 | EP1524963A2 Novel floating dosage form |
| 04/27/2005 | EP1524956A1 Labial product system to maintain a treatment agent |
| 04/27/2005 | EP1424996B1 Method for the production of inhalation powders |
| 04/27/2005 | EP1406590B1 Method for producing articles consisting of polymer materials having a medicamentous depot effect |
| 04/27/2005 | EP1363614B1 Use of 2-amino-1-(4-hydroxy-3-methanesulphonamidophenyl)ethanol for treating urinary incontinence |
| 04/27/2005 | EP1330246B1 Use of hydroxyeicosatetraenoic acid derivatives in intraocular surgery |
| 04/27/2005 | EP1299083B1 Implantable low molecular weight cellulosic compositions |
| 04/27/2005 | EP1253932B1 Botulinum toxin pharmaceutical compositions |
| 04/27/2005 | EP1217993B1 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 04/27/2005 | EP1175220B1 Nanoparticulate eplerenone compositions |
| 04/27/2005 | EP1150707B1 USE OF AN OmpA ENTEROBACTERIUM PROTEIN ASSOCIATED WITH THE ELAGIGILTV PEPTIDE FOR TREATING MELANOMAS |
| 04/27/2005 | EP1116489B1 Oral drug delivery system for enhancing the bioavailability of activated glycyrrhetin |
| 04/27/2005 | EP1105122B1 Pharmaceutical compositions containing lipase inhibitors |
| 04/27/2005 | EP1073470B1 Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients |
| 04/27/2005 | EP1061929B1 Pharmaceutical composition based on natural synthesis progesterone and oestradiol and preparation method |
| 04/27/2005 | EP1003482B1 Microparticles for controlled delivery of biologically active molecules |
| 04/27/2005 | EP0979072B1 Transdermal device for the delivery of testosterone |
| 04/27/2005 | EP0935470B1 Method for treating allergic lung disease |
| 04/27/2005 | CN2694979Y Medicated plaster for treating nasitis |
| 04/27/2005 | CN2694978Y External adhesive plaster |
| 04/27/2005 | CN1610703A Non-aqueous absorbent and use thereof |